EUCTR2011-002566-21-PL进行中（未招募）不适用
A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory C
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 156
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Previous confirmation of B-cell CLL (including SLL) with a characteristic immunophenotype by flow cytometry.
- •Progressive disease after receiving at least one prior line of treatment (a minimum of one course of chemotherapy with rituximab) and not a candidate for HSC or BM transplant
- •Deemed a candidate for bendamustine/rituximab therapy by their treating physician
- •Presence of symptomatic disease
- •Adequate hematological function
- •Adequate organ function
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 130
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 26
排除标准
- •Any chemotherapy, radiotherapy, immunotherapy, biologic, investigational or hormonal therapy for treatment of lymphoma within 28 days prior to treatment
- •Exposure to Bendamustine within 180 days before drug administration
- •Any active secondary malignancy
- •Prior autologous or allogeneic stem cell transplantation SCT
- •Clinically significant abnormality on ECG
- •History of other invasive malignancy within 5 years except for localized/in situ, carcinomas such as cervical carcinoma in situ or basal/squamous skin cancer.
- •Evidence of active infection
- •Documented current central nervous system involvement by leukemia or lymphoma
- •Having Richter’s transformation or high-grade disease
- •Current pregnancy or lactation
- •History of yellow fever vaccination within three months prior to study enrollment
研究者
相似试验
进行中（未招募）
不适用
A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)EUCTR2011-002566-21-BEMedImmune, LLC163
进行中（未招募）
不适用
A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)EUCTR2011-002566-21-ITMEDIMMUNE ONCOLOGY INC156
进行中（未招募）
1 期
A Phase 2 Open-label Study of MEDI-551 and Bendamustine vs Rituximab and Bendamustine in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Relapsed or refractory chronic lymphocytic leukemia (CLL)MedDRA version: 16.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2011-002566-21-DEMedImmune, LLC156
进行中（未招募）
1 期
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Relapsed or refractory diffuse large B-cell lymphoma(DLBCL)MedDRA version: 18.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002565-38-DEMedImmune, LLC180
进行中（未招募）
不适用
A Phase 2 Randomized Open-label Study of MEDI-551 in AdultsWith Relapsed or Refractory DLBCRelapsed or Refractory Diffuse Large B-cell Lymphoma .(DLBCL)MedDRA version: 14.1Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002565-38-ITMEDIMMUNE ONCOLOGY INC170